Breast Cancer Research and Treatment

, Volume 117, Issue 2, pp 453–459 | Cite as

Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases

  • David J. Novak
  • Nelly Sabbaghian
  • Philippe Maillet
  • Pierre O. Chappuis
  • William D. Foulkes
  • Marc Tischkowitz
Brief Report


Background Around half of familial breast cancer cases are caused by germ-line mutations in genes which are critically involved in the maintenance of genome stability. Mutations in related genes functioning in DNA repair may account for currently unattributed cases. Two such genes, RAP80 and Abraxas, have recently been identified to be in a complex with BRCA1, and are required for the localization of BRCA1 to DNA damage foci. Methods RAP80 and Abraxas variants were screened for in a cohort of 95 high risk, non-BRCA1/2 breast cancer cases of varying ethnicity: those of Ashkenazi Jewish (n = 35), mixed Canadian (n = 34) and Swiss descent (n = 26). Results We have identified four missense variants, four silent SNPs, three SNPs in the UTRs and seven intronic variants in RAP80. Two of the previously reported RAP80 variants were further investigated. In Abraxas, we have identified two missense, nine intronic and two variants in the 3′ UTR. Conclusions Overall, it seems unlikely that moderate to highly penetrant alleles of either RAP80 or Abraxas, confer a significantly high relative risk of breast cancer.


Hereditary breast cancer RAP80 Abraxas 



We would like to thank George Chong and Lili Li for their help with this project. The work was funded by grants from the Canadian Breast Cancer Research Alliance (W.D.F. and T.A.B.), Jewish General Hospital Weekend to End Breast Cancer, Rethink Breast Cancer Canada, the Canadian Foundation for Innovation (M.T.). W.D.F. holds a Fonds de la Recherche en Santé du Québec national scientist award. M.T holds a Fonds de la Recherche en Santé du Québec clinician-scientist award.


  1. 1.
    Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124(1):31–42PubMedCrossRefGoogle Scholar
  2. 2.
    Yan Z, Kim YS, Jetten AM (2002) RAP80, a novel nuclear protein that interacts with the retinoid-related testis-associated receptor. J Biol Chem 277(35):32379–32388. doi: 10.1074/jbc.M203475200 PubMedCrossRefGoogle Scholar
  3. 3.
    Sobhian B, Shao G, Lilli DR et al (2007) RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316(5828):1198–1202. doi: 10.1126/science.1139516 PubMedCrossRefGoogle Scholar
  4. 4.
    Liu Z, Wu J, Yu X (2007) CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol 14(8):716–720. doi: 10.1038/nsmb1279 PubMedCrossRefGoogle Scholar
  5. 5.
    Yan J, Kim YS, Yang XP et al (2007) Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor alpha. Nucleic Acids Res 35(5):1673–1686. doi: 10.1093/nar/gkl1112 PubMedCrossRefGoogle Scholar
  6. 6.
    Di Fiore PP, Polo S, Hofmann K (2003) When ubiquitin meets ubiquitin receptors: a signalling connection. Nat Rev Mol Cell Biol 4(6):491–497. doi: 10.1038/nrm1124 PubMedCrossRefGoogle Scholar
  7. 7.
    Kim H, Chen J, Yu X (2007) Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316(5828):1202–1205. doi: 10.1126/science.1139621 PubMedCrossRefGoogle Scholar
  8. 8.
    Yan J, Kim YS, Yang XP et al (2007) The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 67(14):6647–6656. doi: 10.1158/0008-5472.CAN-07-0924 PubMedCrossRefGoogle Scholar
  9. 9.
    Kim H, Huang J, Chen J (2007) CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 14(8):710–715. doi: 10.1038/nsmb1277 PubMedCrossRefGoogle Scholar
  10. 10.
    Akbari MR, Ghadirian P, Robidoux A et al (2008) Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-008-9933-z
  11. 11.
    Wang B, Matsuoka S, Ballif BA et al (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316(5828):1194–1198. doi: 10.1126/science.1139476 PubMedCrossRefGoogle Scholar
  12. 12.
    Shebzukhov YV, Koroleva EP, Khlgatian SV et al (2007) RAP80/UIMC1 as cancer-associated antigen: alternative splice variants and their immunogenicity. Cancer Lett 255(2):255–262. doi: 10.1016/j.canlet.2007.04.013 PubMedCrossRefGoogle Scholar
  13. 13.
    Houlston RS, Peto J (2004) The search for low-penetrance cancer susceptibility alleles. Oncogene 23(38):6471–6476. doi: 10.1038/sj.onc.1207951 PubMedCrossRefGoogle Scholar
  14. 14.
    Osorio A, Barroso A, Garcia MJ et al (2008) Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat. doi: 10.1007/s10549-008-9933-4
  15. 15.
    Venables JP (2007) Downstream intronic splicing enhancers. FEBS Lett 581(22):4127–4131. doi: 10.1016/j.febslet.2007.08.012 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • David J. Novak
    • 1
    • 2
    • 3
  • Nelly Sabbaghian
    • 1
    • 3
  • Philippe Maillet
    • 4
  • Pierre O. Chappuis
    • 5
  • William D. Foulkes
    • 1
    • 2
    • 3
    • 6
  • Marc Tischkowitz
    • 1
    • 2
    • 3
  1. 1.Departments of Oncology and Human Genetics, Program in Cancer GeneticsMcGill UniversityMontrealCanada
  2. 2.Departments of Medicine and Human GeneticsMcGill UniversityMontrealCanada
  3. 3.Segal Cancer CenterMcGill University Sir M. B. Davis-Jewish General HospitalMontrealCanada
  4. 4.Laboratory of Molecular Oncology, Division of Laboratory Medicine, Department of Genetic Medicine and LaboratoryUniversity Hospitals of GenevaGeneva 14Switzerland
  5. 5.Unit of Oncogenetics and Cancer Prevention, Division of Oncology, Department of Internal Medicine; Division of Genetic Medicine, Department of Genetic Medicine and Laboratory University Hospitals of GenevaGeneva 14Switzerland
  6. 6.The Research InstituteMcGill University Health CentreMontrealCanada

Personalised recommendations